The 14 most recent market catalysts affecting $DARE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Neutral
Impact 65
Daré Bioscience Reports Third Quarter 2026 Financial Results
Daré Bioscience announced its Q3 2026 financial results, a routine disclosure for public companies. The key takeaway is the commencement of revenue generation from Flora Sync LF5 i…
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 55
Daré Bioscience Receives Additional Grant Funding for Contraceptive Development
Daré Bioscience announced receiving an $851,796 payment, which is the second-to-last tranche of an up to $10.7 million grant. This funding is specifically allocated for the preclin…
Nov 10, 2026
Corporate Catalyst
Neutral
Impact 55
Daré Bioscience Releases New Episode of 'CEO Corner' Video Series
Daré Bioscience announced a new episode of its 'CEO Corner' video series, focusing on the company's transition to a commercial-stage entity. This matters because it signals progres…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding
Daré Bioscience announced a significant financial milestone, surpassing $43 million in non-dilutive grant funding. This funding directly supports the development of its programmabl…
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 55
Daré Bioscience Participates in Virtual Investor Discussion on Women's Health Executive Order
Daré Bioscience announced its participation in a virtual investor discussion focused on a Women's Health Executive Order. This event is significant because it positions the company…
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 65
Daré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11
Daré Bioscience is presenting positive Phase 1 clinical data for its Sildenafil Cream, 3.6% at a medical conference. The key finding is that the topical cream delivers sildenafil w…
Oct 2, 2026
Corporate Catalyst
Neutral
Impact 65
Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance
Dare Bioscience (DARE) has disclosed receiving a deficiency notice from Nasdaq due to its common stock trading below the minimum $1.00 bid price requirement. This is a significant …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Daré Bioscience Announces $908K NIH Award For Preclinical Development Of DARE-PTB2 In Preterm Birth Prevention, With Recommended Future-Year Support Of About $1.3M
This NIH award is a positive development for Daré Bioscience, providing non-dilutive capital for the preclinical development of DARE-PTB2. This extends the company's cash runway an…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 55
Dare Bioscience Files Prospectus Related To The Resale Of Up To 8,934,345 Shares Of Common Stock By Selling Stockholders
Dare Bioscience has filed a prospectus to register for resale up to 8,934,345 shares of common stock held by various selling stockholders. This action is a standard procedure follo…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 65
Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure
Dare Bioscience (DARE) has announced the publication of Phase 1 clinical study results for its proprietary Sildenafil Cream, 3.6%, in a peer-reviewed journal. The study demonstrate…
Aug 14, 2026
Market Technicals
Bullish
Impact 75
Dare Bioscience Shares Halted On Circuit Breaker To The Downside, Stock Now Up -16.79%
The circuit breaker halt for Dare Bioscience (DARE) shares is a direct consequence of extreme price volatility, specifically a rapid decline. This event signals strong negative sen…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 75
Daré Bioscience Announces $6M Offering Of 4,379,581 Shares (Or Pre-Funded Warrants To Purchase Shares Of Common Stock In Lieu Thereof) At $1.37/Share
Daré Bioscience is conducting a registered direct offering and a concurrent private placement to raise $6 million. This involves issuing new shares and warrants, which will dilute …
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 65
Dare Bioscience shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a direct corporate catalyst, as Dare Bioscience's stock is reacting positively to its own strong financial performance. The impact is moderate because whil…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 92
Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate
Dare Bioscience's Q2 earnings report shows a substantial beat on both EPS and sales estimates. The company's reported loss of $(0.20) per share was better than the $(0.24) consensu…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.